本帖最后由 成长的烦恼 于 2012-6-27 20:19 编辑 6 |; ~3 f. U+ A3 S
9 r7 C W7 H y4 n7 A1 o& d2 Q" C% ]# @clinicaltrials上的三期临床链接, @! t4 r% B, I
1 l* T) d) `" j4 `9 u4 Nhttp://clinicaltrials.gov/ct2/sh ... mp;show_locs=Y#locn' E$ S0 N) _9 c% F+ L, ?1 _9 R* u
# O! p, Z# m) {1 t4 m4 G中国参加临床实验的城市& C* T$ ?: Y4 M0 `; l z
% h4 r# l) `$ `/ _- ~% T6 E5 u4 \
China, Guangdong
\& a9 o+ N1 j' D& ~1 { ! D r9 b% p' r( [
Guangzhou, Guangdong, China, 510515
# D$ F. L) X2 _
$ u% I0 T: h/ {# b2 s+ u, @Guangzhou, Guangdong, China, 510060
, ?% [. N; C6 ?3 a! b' M5 r* v6 P$ iChina, Jiangsu
' h3 d! d) A9 x: o / A9 p2 q9 X0 C, m$ e, {9 _" s
Nanjing, Jiangsu, China, 210009 * h4 [( z: M. q% I8 @
5 ^5 Z# ]" T1 \( V3 a
Nanjing, Jiangsu, China, 210002 5 u/ g8 h/ H8 l3 J6 ~
China, Shandong
$ @ J: T6 X: O n7 J) j
% X5 p; g2 W9 ]4 N' sQingdao, Shandong, China, 266003
9 n* y0 _$ ~. x7 i' I3 P+ QChina 4 g( E5 d1 Y! E4 q) H* x# h
: D% v/ R% V9 P) S' x& }8 l. b
Beijing, China, 100021
' t/ @4 y; a4 m5 V& L ! \) O) i- |% R. n X
Beijing, China, 100071 ' n+ g+ m' N. M# X0 B$ r7 L9 M) V
6 a5 p( [3 }0 r9 |/ I' M7 EChangchun, China, 130021
; s% B6 U0 X# j! k6 ^5 Y
@/ s1 z, M, g( KChongqing, China, 400042 " Q4 B, D9 B: Z& }& `& F" f
7 }. O: |3 {# K$ a& Q, QChongqing, China, 400038 9 X& q4 m; L" a" M# B- \, L4 l
7 V0 G5 Q7 c% e* r' S
Fuzhou, China, 350014 9 N( [' }4 w3 n! ]3 X
: M" \$ _4 v; v/ y4 eFuzhou, China, 350025
3 x9 ~' N" V8 i7 s9 F3 p) i# y
$ D% F+ v! s4 q3 ~$ YHa'erbin, China, 150040 1 L! n' V# H8 X5 y! ^+ B
/ C2 |- v6 y* P+ v B2 iHanghzou, China, 310009
3 N- V: E7 ?4 `7 N
/ B6 Y8 F4 a6 f& }Shanghai, China, 200001 4 \' U/ s* } K5 E
- u' D. v! {! P( d
Shanghai, China, 200030 $ D K1 C% D- E& B
' Z% H/ V+ D/ D' E; C0 ?5 b' u. x9 t
Tianjin, China
! p/ `3 v H. X2 f' j1 {* e* U2 n
6 ^# }5 Q3 E9 F5 o- V: H该实验已停止招募,重新开的临床请见临床专用贴。 |